Keros Therapeutics Inc (KROS)

EBITDA Margin

-562.79%

TTM · Period ending:

KROS logo

KROS EBITDA Margin

Latest reported-562.79%
KROS TTM EBITDA Margin (-87.16% → -562.79%)
High-resolution chart · PNG

KROS ebitda margin history

Trailing twelve months (TTM). Each value covers four complete reported quarters.

Keros Therapeutics Inc EBITDA Margin — Trailing twelve months (TTM)
Period endingEBITDA Margin
-562.7881%
-267.4251%
38.2716%
36.0083%
19.1141%
14.9516%
-4,776.6761%
-27,715.2074%
-61,628.7823%
-68,109.8291%
-100,779.4702%
-1,772,150%
-396.25%
-380.49%
-321.7413%
-280.3582%
-62,115%
-53,846%
-1,400.68%
-530.92%
-241.0933%
-87.16%
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.